Chenland Nutritionals announced no-objection NDIN for JointAlive ingredient

November 16, 2020
Sebastian Krawiec

Chenland Nutritionals Inc. has announced a successful New Dietary Ingredient Notification (NDIN) for its patented JointAlive ingredient.

Chenland Nutritionals Inc. (Irvine, CA) has announced a successful New Dietary Ingredient Notification (NDIN) for its patented JointAlive ingredient. NDINs are required to be submitted to the U.S. Food and Drug Administration (FDA) at least 75 days before introduction to interstate commerce if an ingredient was not marketed in dietary supplements in the U.S. prior to October 15, 1994. FDA acknowledged the notification (report #1172) without objection.

The ingredient is made up of dried powder extracts of Epimedium brevicornum Maxim, Discorea nipponicaMakino and Salvia miltiorrhiza Bunge. The recommended conditions of use cited in the NDIN were “Twice a day, 300 mg each time with a maximum daily serving of 600 mg for up to 4 weeks.” JointAlive is marketed to support joint function such as flexibility and mobility, as well as relieving joint inflammation, and swelling.